Clinical Trials Logo

Filter by:
NCT ID: NCT05589337 Recruiting - Anxiety Symptoms Clinical Trials

Baduanjin Training for Depression and Anxiety Patients

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

In recent years, the number of people with symptoms of depression or anxiety are on the rise. The aims of the prospective randomized study are: (1) to examine the effects of Baduanjin breathing training on reducing symptoms of depression or anxiety, and (2) to explore the correlates between improvements of depression or anxiety symptom and changes of lung functions.

NCT ID: NCT05589207 Recruiting - Clinical trials for Carcinoma, Renal Cell

Predicting Model Based on Evidence-based Pathological Diagnose Criteria for RCC Tumor Thrombus With IVC Wall Invasion

Start date: January 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to establish a preoperative imaging diagnostic model which highly consistent with the histopathological examinations, as well as a accurate and systematic pathological grading standard of inferior vena cava (IVC) vascular wall invasion in renal cell carcinoma (RCC) with tumor thrombus invading vascular wall.The main questions it aims to answer are: - To establish a preoperative imaging diagnostic model which highly consistent with the histopathological examinations. - To determine what impact does different vascular wall layer invasion make on the long-term prognosis in RCC with IVC tumor thrombus; - To determine which layer invasion according to pathological examination make sense to clinical treatment (can significantly affect prognosis); Participants with IVC vascular wall invasion/ non-invasion are divided into experimental group (invaded group) or control group (non-invaded group) respectively according to pathological examinations, in order to establish a prospective cohort with three-year follow-up. The pathological characteristics of local recurrence and poor prognosis are summarized, and postoperative pathological diagnostic criteria of IVC vascular wall invasion and established. The local recurrence and distant recurrence outcomes are compared between experiment group and control group, in order to analyze the long-term influence of vascular wall invasion. Then the preoperative imaging diagnostic evaluation model will be established.

NCT ID: NCT05588921 Recruiting - Lens Opacities Clinical Trials

LensAge to Reveal Biological Age

Start date: January 1, 2020
Phase:
Study type: Observational

Assessment of aging is central to health management. Compared to chronological age, biological age can better reflect the aging process and health status; however, an effective indicator of biological age in clinical practice is lacking. Human lens accumulates biological changes during aging and is amenable to a rapid and objective assessment. Therefore, the investigators will develop LensAge as an innovative indicator to reveal biological age based on deep learning using lens photographs.

NCT ID: NCT05588908 Recruiting - Acute Gout Clinical Trials

A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Start date: June 29, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the target dose of phase II and to evaluate the safety, tolerability, pharmacokinetics and efficacy of recombinant anti-IL-1β humanized monoclonal antibody injection at different doses in Chinese participants with acute gout.

NCT ID: NCT05588843 Recruiting - Colitis Ulcerative Clinical Trials

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

RESOLUTE
Start date: November 25, 2022
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of SAR443122 compared to placebo in participants with moderate to severe UC. Dose selection for further clinical development will be based on the multiple efficacy, safety and PK parameters. The study consists of 4 parallel arms (3 dose groups of SAR443122 vs placebo) to assess the efficacy and safety of SAR443122 in participants with moderate to severe UC. All participants will receive a total of 52 weeks (a 12-week induction treatment phase and a 40-week maintenance phase) of study treatment, except if treatment should be discontinued per investigator's assessment. At the end of the first 12 weeks of induction treatment, all participants in clinical response or remission will be offered study treatment up to 40 weeks and will continue with the same blinded treatment that was assigned. Participants who do not achieve clinical response or remission at the end of the initial 12 weeks induction treatment will roll over in an open-label treatment arm and will be treated with SAR443122 at the highest tested dose. In addition, participants from the maintenance treatment that lose clinical efficacy at any time up to V10/Week 40 (Week 28 of maintenance) will be offered to roll over in the open-label treatment arm with SAR443122 at the highest dose.

NCT ID: NCT05588596 Completed - HIV Clinical Trials

Intervention Program to Address PTSD in People Living With HIV

Start date: May 3, 2020
Phase: N/A
Study type: Interventional

The goal of this randomised controlled trial is to evaluate the efficacy of an integrated intervention program on post-traumatic stress disorder (PTSD) symptoms and related physiological and psychological indicators of people living with HIV (PLWH). The main question it aims to answer are: - to evaluate the efficacy of the intervention program on PTSD symptoms and related physiological and psychological indicators of PLWH through empirical research. - to analyze the mechanism of the intervention. Eligible PLWH were recruited and randomly divided as intervention group and control group. The efficacy of Trauma Resiliency Mindfulness-Informed Intervention on PTSD symptoms and related physiological and psychological indicators in PLWH was evaluated at baseline, after intervention, and 3 months after intervention through this randomized controlled trial. Researchers compared the intervention group and control group to see if it was feasible and had potential clinical value to introduce the Trauma Resiliency Mindfulness-Informed intervention program into the management of PLWH in China.

NCT ID: NCT05588531 Completed - Pharmacokinetics Clinical Trials

Study on Tolerance, Pharmacokinetics and Drug Interaction of YK-1169 in Healthy Volunteers

Start date: December 20, 2021
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of multiple doses of YK-1169 in healthy subjects, the pharmacokinetic characteristics of multiple doses in healthy subjects, and the drug interaction between cefepime and avibactam.

NCT ID: NCT05588284 Enrolling by invitation - Clinical trials for Acute Deep Venous Thrombosis of Femoral Vein (Disorder)

Preservation of Venous Valvular Function After PMT for Acute DVT

PREFER
Start date: June 6, 2022
Phase: N/A
Study type: Interventional

To evaluate the venous valvular function after pharmacomechanical thrombectomy (PMT) for acute femoral-popliteal venous thrombosis.

NCT ID: NCT05588271 Recruiting - Clinical trials for Liver Transplantation

A New Prediction Mode for Predicting the Risk of Pressure Injury in Patients Undergoing Liver Transplantation

PMPRPIULT
Start date: October 20, 2022
Phase:
Study type: Observational

Pediatric population is at a high-risk of pressure injury (PI). Patients undergoing liver transplantation are more prone to PIs compared with other types of surgery. However, there is a lack of sensitive and specific assessment tools for the risk of PI in patients undergoing liver transplantation. How to accurately predict the incidence of PI in patients undergoing liver transplantation is needs to be urgently eliminated. The study is conducted in the Renji Hospital, School of Medicine, Shanghai Jiaotong University which is the largest liver transplantation center in China.

NCT ID: NCT05588219 Recruiting - Clinical trials for Uterine Cervical Neoplasms

Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Start date: December 1, 2022
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the efficacy and safety of Tislelizumab combined with concurrent chemoradiotherapy in the treatment of cervical cancer patients with cervical mass > 4cm and regional lymph node metastasis, paracervical invasion and regional lymph node metastasis, stage IIIA, stage IIIB, and stage IVA. To provide a clinical reference for finding a safe and effective individualized treatment plan to improve the survival prognosis of locally advanced cervical cancer patients.